The stock of Alkermes Plc Ord (NASDAQ:ALKS) registered an increase of 11.15% in short interest. ALKS’s total short interest was 4.87 million shares in September as published by FINRA. Its up 11.15% from 4.38M shares, reported previously. With 744,000 shares average volume, it will take short sellers 7 days to cover their ALKS’s short positions. The short interest to Alkermes Plc Ord’s float is 3.79%. The stock decreased 1.21% or $0.58 during the last trading session, hitting $47.16. About 509,427 shares traded hands. Alkermes Plc (NASDAQ:ALKS) has risen 62.11% since February 8, 2016 and is uptrending. It has outperformed by 45.62% the S&P500.
Alkermes Public Limited Company is a biopharmaceutical company. The company has a market cap of $7.52 billion. The Firm is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. It currently has negative earnings. The Firm has a portfolio of approximately 20 products and a clinical pipeline of product candidates that address central nervous system disorders, such as schizophrenia, depression, addiction and multiple sclerosis.
The institutional sentiment increased to 0.96 in 2016 Q2. Its up 0.25, from 0.71 in 2016Q1. The ratio is positive, as 31 funds sold all Alkermes Plc shares owned while 75 reduced positions. 34 funds bought stakes while 68 increased positions. They now own 135.77 million shares or 0.84% less from 136.92 million shares in 2016Q1.
Meditor Group Ltd holds 18.13% of its portfolio in Alkermes Plc for 1.03 million shares. Opus Point Partners Management Llc owns 82,858 shares or 3.46% of their US portfolio. Moreover, Roanoke Asset Management Corp Ny has 2.1% invested in the company for 104,962 shares. The Massachusetts-based Camber Capital Management Llc has invested 1.96% in the stock. Twin Focus Capital Partners Llc, a Massachusetts-based fund reported 40,000 shares.
Out of 7 analysts covering Alkermes (NASDAQ:ALKS), 4 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 57% are positive. Alkermes has been the topic of 12 analyst reports since October 7, 2015 according to StockzIntelligence Inc. Barclays Capital maintained the stock on July 29 with “Overweight” rating.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.